Eosinophilic Esophagitis

Researchers will study connections between eosinophilic esophagitis and interferon signaling, possibly paving the way for new treatments, with funding from the AAAAI Foundation’s 2023 Faculty Development awards.

Healio compiled the most-read news in allergy, asthma and immunology posted in May.

Adolescents and adults experienced sustained improvements in eosinophilic esophagitis outcomes with dupilumab for up to 52 weeks, according to research presented at Digestive Disease Week 2023 in Chicago.

CHICAGO — In this Healio video, Evan S. Dellon, MD, MPH, explains that while mepolizumab outperformed placebo at 3 months, there were no additional symptom or endoscopic improvements at 6 months in patients with eosinophilic esophagitis.

Healio compiled the most-read news in allergy, asthma and immunology posted in April.

Researchers identified treatment disparities between incarcerated people with asthma and other chronic health conditions compared with the general population, highlighting an opportunity to improve health outcomes in this population.

Many children and adults outgrow their food allergies, recent data show.

Patients with eosinophilic esophagitis taking a first-in-class peptide during a phase 2a randomized, double-blind clinical trial safely experienced reductions in esophageal intraepithelial eosinophil count, according to a press release.

Most patients who developed eosinophilic esophagitis during oral immunotherapy experienced resolution in their EoE symptoms without stopping OIT, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.